Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

CD3 T cell

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CD3 (24) Itk (1) Apoptosis (3) CD19 (1) CD2 (1) CD20 (5) CD28 (1) Interleukin Related (2) MAP4K (1) Notch (2) Nuclear Factor of activated T Cells (NFAT) (1) PD-1/PD-L1 (3) PROTACs (1) Src (1) TNF Receptor (1)
By Research Areas:	Cancer (33) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (13) Neurological Disease (1)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

MCE Kits

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

Targets Recommended: CD3 Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3 BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99523

Vepsitamab AMG 199	CD3	Cancer
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .

HY-P99392

Teclistamab	CD3	Cancer
Teclistamab is a human bispecific antibody to BCMA and *CD3* that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .

HY-P99390

Tepoditamab MCLA 117	CD3	Cancer
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and *CD3* of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research .

HY-P99152

Muromonab	CD3	Inflammation/Immunology Cancer
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection .

HY-P99802

Pasotuxizumab BAY 2010112; AMG 212	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and *CD3* bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99038

Odronextamab	CD20 CD3	Inflammation/Immunology Cancer
Odronextamab is a stable humanized IgG4 CD20 × *CD3* bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational *CD123/CD3* bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and *CD3* in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-P99757

Nivatrotamab Hu3F8-BsAb	CD2 CD3	Cancer
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .

HY-P99837

Dafsolimab SPV-T3a	CD3	Infection
Dafsolimab (SPV-T3a) is an IgG2a murine monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) .

HY-P990785

ABBV-383 TNB 383B; Etentamig	CD3	Cardiovascular Disease Inflammation/Immunology Cancer
ABBV-383 (ABBV-383) is a BCMA × *CD3* bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein *CD3* complex. ABBV-383 can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .

HY-P99931

Epcoritamab GEN3013	CD3 CD20	Cancer
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .

HY-P99350

Gresonitamab AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets *CD3*-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .

HY-P99762

Obrindatamab MGD009	CD3	Cancer
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .

HY-P99011

Cibisatamab	CD3	Cancer
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and *CD3* on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .

HY-130625

PD-1/PD-L1-IN 6	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN 6 (compound A13) is a potent PD-1/PD-L1 interaction inhibitor, with an IC₅₀ of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model .

HY-131183

PROTAC PD-1/PD-L1 degrader-1	PROTACs PD-1/PD-L1	Inflammation/Immunology
PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner .

HY-P99521

Vibecotamab XmAb14045	CD3	Cancer
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and *CD3* that stimulates T cell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies .

HY-P99601

Cevostamab BFCR 4350A; RG 6160; RO 7187797	CD3	Neurological Disease Cancer
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as *CD3* on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .

HY-P99776

Plamotamab XmAb-13676	CD20 CD3	Cancer
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds *CD3* and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 ⁺ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .

HY-P99562

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-156520

Immunosuppressant-1	Apoptosis	Inflammation/Immunology
Immunosuppressant-1 (Compound 31) inhibits anti-CD3/anti-CD28 co-stimulated T-cell proliferation. Immunosuppressant-1 has immunosuppressive activity, and induces apoptosis by activating caspase-3 and PARP in activated lymph node cells .

HY-159123

KHK-6	MAP4K	Cancer
KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC₅₀ of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .

HY-P99033

Mosunetuzumab BTCT-4465A	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and *CD3* (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

HY-P99394

Talquetamab JNJ-64407564	CD3	Cancer
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and *CD3* to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .

HY-19486

UR-1505	Nuclear Factor of activated T Cells (NFAT) CD3 CD28 Interleukin Related	Inflammation/Immunology
UR-1505 is a *nuclear factor of activated T cells* (NF-AT) inhibitor. UR-1505 can suppress CD3/CD28** induced T cell proliferation, increase p27 ^KIP levels, and induce G1/S cell cycle arrest. UR-1505 can also inhibit the production of IL-5 and IFN-γ in activated T cells. UR-1505 has immunomodulatory properties and can be used in the study of atopic dermatitis .

HY-P99024

Glofitamab RO7082859	CD20 CD3	Inflammation/Immunology Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for *CD3* on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .

HY-P990104

Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757)	Notch	Inflammation/Immunology Cancer
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.

HY-P99339

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells* to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

HY-P99814

Pavurutamab AMG-701	CD3	Inflammation/Immunology Cancer
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-*B cell* maturation antigens (BCMA**). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .

HY-120622

BMS-243117	Src	Cancer
BMS-243117 is a potent, and selective benzothiazole based p56 ^Lck inhibitor with an IC₅₀ of 4 nM. BMS-243117 inhibits anti-CD3/anti-CD28 induced PBL (human peripheral blood T-cells) proliferation with an IC₅₀ of 1.1 μM. BMS-243117 binds in an extended conformation to the ATP-binding site of Lck .

HY-149917

ITK degrader 1	Itk	Cancer
ITK degrader 1 is a highly selective degrader of *interleukin-2-inducible T-cell* kinase (ITK; DC₅₀*=3.6 nM in vivo* in mice). ITK degrader 1 induces rapid, and prolonged ITK degradation and suppresses IL-2 secretion (EC₅₀=35.2 nM, Jurkat cells) stimulated by anti-CD3 antibodyin vivo. ITK degrader 1 also shows good plasma exposure levels .

HY-P99575

Tarlatamab AMG-757	Notch	Inflammation/Immunology Cancer
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the K_Ds of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the K_Ds of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .

HY-145288

Antitumor agent-36	Apoptosis	Cancer
Antitumor agent-36 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-36 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-36 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-36 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues .

HY-145289

Antitumor agent-37	Apoptosis	Cancer
Antitumor agent-37 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-37 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-37 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-37 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues .

HY-P99798

Pacanalotamab AMG 420; BI-836909	CD3	Cancer
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and *CD3E. BCMA refers to B cell* maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .

HY-P9963

Blinatumomab 1 Publications Verification Anatumomab	CD19	Cancer
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for *CD3E* on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .

HY-P99345

Dostarlimab TSR-042	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

Cat. No.	Product Name

HY-K0304

Human CD3⁺ T Cells Negative Selection Kit
MCE Human CD3⁺ T Cells Negative Selection Kit is designed for the isolation of CD3⁺ T cells from human peripheral blood mononuclear cells (PBMC).

HY-K0306

Mouse CD3⁺ T Cells Negative Selection Kit
MCE Mouse CD3⁺ T Cells Negative Selection Kit is designed for the isolation of CD3⁺ T cells from single cell suspensions of mouse spleen cells and lymph nodes.

Cat. No.	Product Name	Target	Research Area

HY-P99523

Vepsitamab AMG 199	CD3	Cancer
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .

HY-P99392

Teclistamab	CD3	Cancer
Teclistamab is a human bispecific antibody to BCMA and *CD3* that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .

HY-P99390

Tepoditamab MCLA 117	CD3	Cancer
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and *CD3* of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research .

HY-P99152

Muromonab	CD3	Inflammation/Immunology Cancer
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection .

HY-P99802

Pasotuxizumab BAY 2010112; AMG 212	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and *CD3* bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99038

Odronextamab	CD20 CD3	Inflammation/Immunology Cancer
Odronextamab is a stable humanized IgG4 CD20 × *CD3* bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational *CD123/CD3* bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and *CD3* in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-P99757

Nivatrotamab Hu3F8-BsAb	CD2 CD3	Cancer
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .

HY-P99837

Dafsolimab SPV-T3a	CD3	Infection
Dafsolimab (SPV-T3a) is an IgG2a murine monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) .

HY-P990785

ABBV-383 TNB 383B; Etentamig	CD3	Cardiovascular Disease Inflammation/Immunology Cancer
ABBV-383 (ABBV-383) is a BCMA × *CD3* bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein *CD3* complex. ABBV-383 can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .

HY-P99931

Epcoritamab GEN3013	CD3 CD20	Cancer
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .

HY-P99350

Gresonitamab AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets *CD3*-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .

HY-P99762

Obrindatamab MGD009	CD3	Cancer
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .

HY-P99011

Cibisatamab	CD3	Cancer
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and *CD3* on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .

HY-P99521

Vibecotamab XmAb14045	CD3	Cancer
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and *CD3* that stimulates T cell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies .

HY-P99601

Cevostamab BFCR 4350A; RG 6160; RO 7187797	CD3	Neurological Disease Cancer
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as *CD3* on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .

HY-P99776

Plamotamab XmAb-13676	CD20 CD3	Cancer
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds *CD3* and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 ⁺ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .

HY-P99562

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-P99033

Mosunetuzumab BTCT-4465A	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and *CD3* (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

HY-P99394

Talquetamab JNJ-64407564	CD3	Cancer
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and *CD3* to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .

HY-P99024

Glofitamab RO7082859	CD20 CD3	Inflammation/Immunology Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for *CD3* on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .

HY-P990104

Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757)	Notch	Inflammation/Immunology Cancer
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.

HY-P99339

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells* to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

HY-P99814

Pavurutamab AMG-701	CD3	Inflammation/Immunology Cancer
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-*B cell* maturation antigens (BCMA**). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .

HY-P99575

Tarlatamab AMG-757	Notch	Inflammation/Immunology Cancer
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the K_Ds of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the K_Ds of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .

HY-P99798

Pacanalotamab AMG 420; BI-836909	CD3	Cancer
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and *CD3E. BCMA refers to B cell* maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .

HY-P9963

Blinatumomab 1 Publications Verification Anatumomab	CD19	Cancer
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for *CD3E* on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .

HY-P99434

Amlitelimab KY1005; SAR445229	Inhibitory Antibodies	Inflammation/Immunology
Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis .

HY-P99345

Dostarlimab TSR-042	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99523

Vepsitamab AMG 199	Classification of Application Fields Disease Research Fields Cancer	CD3
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .

HY-P99392

Teclistamab	Classification of Application Fields Disease Research Fields Cancer	CD3
Teclistamab is a human bispecific antibody to BCMA and *CD3* that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .

HY-P99152

Muromonab	Classification of Application Fields Disease Research Fields Cancer	CD3
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection .

HY-P99802

Pasotuxizumab BAY 2010112; AMG 212	Classification of Application Fields Disease Research Fields Cancer	CD3
Pasotuxizumab (BAY 2010112) is a PSMA and *CD3* bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99038

Odronextamab	Classification of Application Fields Disease Research Fields Cancer	CD20 CD3
Odronextamab is a stable humanized IgG4 CD20 × *CD3* bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .

HY-P99623

Flotetuzumab MGD006; S80880	Classification of Application Fields Disease Research Fields Cancer	CD3
Flotetuzumab (MGD006; S80880) is an investigational *CD123/CD3* bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and *CD3* in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-P99931

Epcoritamab GEN3013	Classification of Application Fields Disease Research Fields Cancer	CD3 CD20
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .

HY-P99762

Obrindatamab MGD009	Classification of Application Fields Disease Research Fields Cancer	CD3
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .

HY-P99011

Cibisatamab	Classification of Application Fields Disease Research Fields Cancer	CD3
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and *CD3* on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .

HY-P99521

Vibecotamab XmAb14045	Classification of Application Fields Disease Research Fields Cancer	CD3
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and *CD3* that stimulates T cell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies .

HY-P99601

Cevostamab BFCR 4350A; RG 6160; RO 7187797	Classification of Application Fields Disease Research Fields Cancer	CD3
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as *CD3* on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .

HY-P99776

Plamotamab XmAb-13676	Classification of Application Fields Disease Research Fields Cancer	CD20 CD3
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds *CD3* and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 ⁺ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .

HY-P99562

Tidutamab XmAb-18087	Classification of Application Fields Disease Research Fields Cancer	CD3
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-P99033

Mosunetuzumab BTCT-4465A	Classification of Application Fields Disease Research Fields Cancer	CD20 CD3
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and *CD3* (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

HY-P99394

Talquetamab JNJ-64407564	Classification of Application Fields Disease Research Fields Cancer	CD3
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and *CD3* to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .

HY-P99024

Glofitamab RO7082859	Classification of Application Fields Disease Research Fields Cancer	CD20 CD3
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for *CD3* on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .

HY-P99339

Tebentafusp IMCgp100	Classification of Application Fields Disease Research Fields Cancer	Interleukin Related TNF Receptor
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells* to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

HY-P99814

Pavurutamab AMG-701	Classification of Application Fields Disease Research Fields Cancer	CD3
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-*B cell* maturation antigens (BCMA**). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .

HY-P99575

Tarlatamab AMG-757	Classification of Application Fields Disease Research Fields Cancer	Notch
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the K_Ds of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the K_Ds of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .

HY-P99798

Pacanalotamab AMG 420; BI-836909	Classification of Application Fields Disease Research Fields Cancer	CD3
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and *CD3E. BCMA refers to B cell* maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .

HY-P9963

Blinatumomab 1 Publications Verification Anatumomab	Classification of Application Fields Disease Research Fields Cancer	CD19
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for *CD3E* on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .

HY-P99345

Dostarlimab TSR-042	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

Species:	Human (7) Rhesus Macaque (2) Rat (1) Mouse (2) Cynomolgus (4) Canine (2)
Tag:	His (7) Tag Free (1) Fc (10) Flag (1)
Source:	HEK293 (15) P. pastoris (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P72728

	CD3 delta Protein, Cynomolgus (HEK293, His) T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD3d; CD3D	Cynomolgus	HEK293
	CD3 δ protein is a component of the TCR-CD3 complex on T lymphocytes and plays a crucial role in adaptive immunity. Activated by APC, TCR signals through the CD3 chain, including CD3D, CD3E, CD3G, and CD3Z. CD3 delta Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD3 delta protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD3 delta Protein, Cynomolgus (HEK293, His) is 84 a.a., with molecular weight of 20-35 kDa.

HY-P70506

	CD3 epsilon Protein, Human (HEK293, His) T-cell Surface Glycoprotein CD3 Epsilon Chain; T-cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3 epsilon Protein, Human (HEK293, His) is the recombinant human-derived CD3 epsilon protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD3 epsilon Protein, Human (HEK293, His) is 104 a.a., with molecular weight of ~18.0 kDa.

HY-P76788

	CD3 epsilon Protein, Rat (HEK293, Fc) T-cell Surface Glycoprotein CD3 Epsilon Chain; T-cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Rat	HEK293
	CD3 epsilon Protein, a vital component of the TCR-CD3 complex on T-lymphocytes, is pivotal for adaptive immune responses. CD3E is crucial for proper T-cell development and contributes to TCR-CD3 complex internalization and down-regulation. CD3 epsilon Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD3 epsilon Protein, Rat (HEK293, Fc) is 80 a.a., with molecular weight of ~36.1 KDa.

HY-P77320

	CD3 epsilon Protein, Canine (HEK293, Fc) T-cell Surface Glycoprotein CD3 Epsilon Chain; T-cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Canine	HEK293
	The CD3 ε protein on lymphocytes is a component of the TCR-CD3 complex and is critical for adaptive immune responses. When APC is activated, TCR signals transmitted by CD3D, CD3E, CD3G, and CD3Z initiate pathways through ITAM. CD3 epsilon Protein, Canine (HEK293, Fc) is the recombinant canine-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P76220

	CD3 zeta/CD247 Protein, Human (His) T-cell surface glycoprotein CD3 zeta chain; CD247; CD3Z; T3Z; TCRZ	Human	E. coli
	CD3 zeta/CD247 is a component of the TCR-CD3 complex and can transmit APC-induced TCR signals to initiate immune responses. CD3D, CD3E, CD3G, and CD3Z contain ITAMs that are phosphorylated by LCK and FYN upon TCR engagement, providing docking sites for ZAP70. CD3 zeta/CD247 Protein, Human (GST) is the recombinant human-derived CD3 zeta/CD247 protein, expressed by E. coli , with N-GST labeled tag. The total length of CD3 zeta/CD247 Protein, Human (GST) is 113 a.a., with molecular weight of 28-43 KDa.

HY-P76791

	CD3 epsilon Protein, Rhesus Macaque (HEK293, His) T-cell Surface Glycoprotein CD3 Epsilon Chain; T-cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Rhesus Macaque	HEK293
	CD3 epsilon Protein, a vital component of the TCR-CD3 complex on T-lymphocytes, is pivotal for adaptive immune responses. CD3E is crucial for proper T-cell development and contributes to TCR-CD3 complex internalization and down-regulation. CD3 epsilon Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived CD3 epsilon protein, expressed by HEK293 , with C-His labeled tag.

HY-P71723

	CD3 epsilon Protein, Mouse (P.pastoris, His) CD3eT-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain; CD antigen CD3e	Mouse	P. pastoris
	The CD3 epsilon protein is an important component of the TCR-CD3 complex on T lymphocytes and is critical for adaptive immune responses. After APC activates TCR, CD3E, together with CD3D, CD3G and CD3Z, transmits signals through ITAM and activates downstream pathways. CD3 epsilon Protein, Mouse (P.pastoris, His) is the recombinant mouse-derived CD3 epsilon protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of CD3 epsilon Protein, Mouse (P.pastoris, His) is 86 a.a., with molecular weight of ~11.9 kDa.

HY-P70091

	CD3 delta Protein, Cynomolgus (HEK293, Fc) rCynT-cell surface glycoprotein CD3 delta chain/CD3d, Fc ; T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD3d; CD3D	Cynomolgus	HEK293
	CD3 δ protein is a component of the TCR-CD3 complex on T lymphocytes and plays a crucial role in adaptive immunity. Activated by APC, TCR signals through the CD3 chain, including CD3D, CD3E, CD3G, and CD3Z. CD3 delta Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived CD3 delta protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD3 delta Protein, Cynomolgus (HEK293, Fc) is 84 a.a., with molecular weight of ~35.0 kDa.

HY-P71845

	CD3 gamma Protein, Cynomolgus (P.pastoris, His) CD3GT-cell surface glycoprotein CD3 gamma chain; T-cell receptor T3 gamma chain; CD antigen CD3g	Cynomolgus	P. pastoris
	CD3γ protein on lymphocytes is a component of the TCR-CD3 complex and is critical for adaptive immune responses. When the TCR is activated, CD3D, CD3E, CD3G, and CD3Z transmit TCR-mediated signals and activate downstream pathways. CD3 gamma Protein, Cynomolgus (P.pastoris, His) is the recombinant cynomolgus-derived CD3 gamma protein, expressed by P. pastoris , with N-His labeled tag. The total length of CD3 gamma Protein, Cynomolgus (P.pastoris, His) is 91 a.a., with molecular weight of ~12.5 kDa.

HY-P76789

	CD3 epsilon Protein, Rhesus Macaque (HEK293, Fc) T-cell Surface Glycoprotein CD3 Epsilon Chain; T-cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Rhesus Macaque	HEK293
	CD3 epsilon Protein, a vital component of the TCR-CD3 complex on T-lymphocytes, is pivotal for adaptive immune responses. CD3E is crucial for proper T-cell development and contributes to TCR-CD3 complex internalization and down-regulation. CD3 epsilon Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P70682

	CD3 epsilon Protein, Human (104a.a, HEK293, Fc) T-cell Surface Glycoprotein CD3 Epsilon Chain; T-cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3 epsilon Protein, Human (104a.a, HEK293, Fc) is the recombinant human-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD3 epsilon Protein, Human (104a.a, HEK293, Fc) is 104 a.a., with molecular weight of 40-50 kDa.

HY-P70824

	CD3 epsilon Protein, Human (27a.a, HEK293, Fc) T-cell Surface Glycoprotein CD3 Epsilon Chain; T-cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3 epsilon Protein, Human (27a.a, HEK293, Fc) is the recombinant human-derived CD3 epsilon protein, expressed by HEK293 , with C-mFc labeled tag. The total length of CD3 epsilon Protein, Human (27a.a, HEK293, Fc) is 27 a.a., with molecular weight of 32-40 kDa.

HY-P7879

	CD3D Protein, Human (HEK293, His) rHuT-cell surface glycoprotein CD3 delta chain/CD3D, His; T-cell Surface Glycoprotein CD3 Delta Chain; T-cell Receptor T3 Delta Chain; CD3d; CD3D; T3D	Human	HEK293
	CD3D protein is a component of the TCR-CD3 complex on T lymphocytes and plays a key role in adaptive immunity. It transmits signals through the CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D Protein, Human (HEK293, His) is the recombinant human-derived CD3D protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD3D Protein, Human (HEK293, His) is 84 a.a., with molecular weight of 18-30 kDa.

HY-P72899

	CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc-Flag & mFc) T-cell surface glycoprotein CD3 epsilon chain; CD3E; T3E; CD3 epsilon	Human	HEK293
	CD3 epsilon, a crucial part of the TCR-CD3 complex on T-lymphocytes, facilitates TCR-mediated signal transmission. When APCs activate TCR, CD3 epsilon, with CD3D, CD3G, and CD3Z, relays signals across the cell membrane via ITAMs. LCK and FYN phosphorylate CD3 epsilon upon TCR engagement, initiating downstream signaling. Essential for T-cell development, CD3 epsilon forms heterodimers, initiating TCR-CD3 complex assembly. It's vital for TCR-CD3 complex internalization and down-regulation, interacting with CD6, NCK1, and NUMB, underscoring its pivotal role in T-cell processes. CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc-Flag & mFc) is a recombinant protein dimer complex containing human-derived CD3E-CD3G Heterodimer protein, expressed by HEK293, with C-hFc, C-Flag, C-mFc labeled tag. CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc-Flag & mFc), has molecular weight of 42-47 kDa.

HY-P75654

	CD3D Protein, Mouse (HEK293, Fc) T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; T3d	Mouse	HEK293
	The CD3D protein is an important component of the TCR-CD3 complex on T lymphocytes and is critical for adaptive immune responses. After APC activates TCR, CD3D, together with CD3E, CD3G and CD3Z, transmits signals through ITAM and activates downstream pathways. CD3D Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CD3D protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD3D Protein, Mouse (HEK293, Fc) is 105 a.a., with molecular weight of 48-65 kDa.

HY-P70090

	CD3 epsilon Protein, Cynomolgus (HEK293, Fc) rCynT-cell surface glycoprotein CD3 epsilon chain/CD3E, Fc ; CD3 epsilon; CD3e antigen; CD3e antigen, epsilon polypeptide (TiT3 complex); CD3e molecule, epsilon (CD3-TCR complex); CD3e; CD3-epsilon; FLJ18683; T3E; T-cell antigen receptor complex, epsilon subunit of T3; T-cell surface antigen T3/Leu-4 epsilon chain	Cynomolgus	HEK293
	The CD3E/CD3 epsilon 1-27 peptide is critical in the TCR-CD3 complex, transmitting signals during T cell activation. When APC activates the TCR, CD3E undergoes LCK/FYN-mediated phosphorylation together with ITAM, initiating downstream signaling. CD3 epsilon Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived CD3 epsilon protein, expressed by HEK293 , with C-Fc, C-hFc labeled tag. The total length of CD3 epsilon Protein, Cynomolgus (HEK293, Fc) is 96 a.a., with molecular weight of 38-55 kDa.

HY-P76803

	CD3D Protein, Canine (HEK293, Fc) T-cell Surface Glycoprotein CD3 Delta Chain; T-cell Receptor T3 Delta Chain; CD3d; CD3D; T3D	Canine	HEK293
	CD3D protein is a component of the TCR-CD3 complex on T lymphocytes and plays a key role in adaptive immunity. It transmits signals through the CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D Protein, Canine (HEK293, Fc) is the recombinant canine-derived CD3D protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P74301

	CD3D-CD3E Heterodimer Protein, Human (HEK293) T-cell receptor T3 delta chain; CD3D; T3D; CD3E; T3E	Human	HEK293
	CD3D Protein, an integral part of the TCR-CD3 complex on T-lymphocytes, plays a pivotal role in adaptive immunity. It transmits signals through CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D is essential for thymocyte differentiation, ensuring proper TCR-CD3 complex assembly and surface expression. Interacting with CD4 and CD8 coreceptors, CD3D establishes a functional link crucial for CD4 or CD8 T-cell activation and positive selection. Its multifaceted role orchestrates intricate T-cell responses. CD3D-CD3E Heterodimer Protein, Human (HEK293) is a recombinant protein dimer complex containing human-derived CD3D-CD3E Heterodimer protein, expressed by HEK293, with tag free. CD3D-CD3E Heterodimer Protein, Human (HEK293), has molecular weight of 44-54 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80598

	CD3 epsilon Antibody CD3E; T3E; T-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e	WB, IHC-P, IP	Human
	CD3 epsilon Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 23 kDa, targeting to CD3 epsilon. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human.

HY-P80600

	CD3D Antibody CD3D; T3D; T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD antigen CD3d	WB, IHC-F, IHC-P, ICC/IF, IP	Human
	CD3D Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 19 kDa, targeting to CD3D. It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human.

HY-P82680

	Phospho-CD3 zeta (Tyr142) Antibody (YA2425) CD247; CD3Z; T3Z; TCRZ; T-cell surface glycoprotein CD3 zeta chain; T-cell receptor T3 zeta chain; CD antigen CD247	WB, IP	Human
	Phospho-CD3 zeta (Tyr142) Antibody (YA2425) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2425), targeting Phospho-CD3 zeta (Tyr142), with a predicted molecular weight of 19 kDa (observed band size: 19 kDa). Phospho-CD3 zeta (Tyr142) Antibody (YA2425) can be used for WB, IP experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-159123

KHK-6		Azide
KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC₅₀ of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CD3 T cell

Inhibitors & Agonists

MCE Kits

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Antibodies

Click Chemistry

Natural
Products